The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Drug interactions involving the new second- and third-generation antiepileptic drugs
Open accessAbstract
During the period 1989-2009, 14 new antiepileptic drugs (AEDs) were licensed for clinical use and these can be subdivided into new second- and third-generation AEDs. The second-generation AEDs comprise felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. The third-generation AEDs comprise eslicarbazepine acetate and lacosamide. The interaction propensity of AEDs is very important because all new AEDs are licensed, at least in the first instance, as adjunctive therapy. The present review summarizes the interactions (pharmacokinetic and pharmacodynamic) that have been reported with the newer AEDs. The pharmacokinetic interactions include those relating to protein-binding displacement from albumin in blood, and metabolic inhibitory and induction interactions occurring in the liver. Overall, the newer AEDs are less interacting because their pharmacokinetics are more favorable and many are minimally or not bound to blood albumin (e.g., eslicarbazepine, felbamate, gabapentin, lacosamide levetiracetam, rufinamide, topiramate and vigabatrin) and are primarily renally excreted or metabolized by noncytochrome P450 or uridine glucoronyl transferases (e.g., gabapentin, lacosamide levetiracetam, rufinamide, topiramate and vigabatrin) as opposed to hepatic metabolism which is particularly amenable to interference. Gabapentin, lacosamide, levetiracetam, pregabalin and vigabatrin are essentially not associated with clinically significant pharmacokinetic interactions. Of the new AEDs, lamotrigine and topiramate are the most interacting. Furthermore, the metabolism of lamotrigine is susceptible to both enzyme inhibition and enzyme induction. While the metabolism of felbamate, tiagabine, topiramate and zonisamide can be induced by enzyme-inducing AEDs, they are less vulnerable to inhibition by valproate. Noteworthy is the fact that only five new AEDs (eslicarbazepine, felbamate, oxcarbazepine, rufinamide and topiramate) interact with oral contraceptives and compromise contraception control. The most clinically significant pharmacodynamic interaction is that relating to the synergism of valproate and lamotrigine for complex partial seizures. Compared with the first-generation AEDs, the new second- and third-generation AEDs are less interacting, and this is a desirable development because it allows ease of prescribing by the physician and less complicated therapeutic outcomes and complications for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patsalos, P. N., Berry, D. J., Bourgeois, B. F. D., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., Leppik, I. E., Tomson, T., & Perucca, E. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01561.x · Cited by 1,156
Self-citationClinically relevant drug interactions with antiepileptic drugs
Perucca, E. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02529.x · Cited by 602
Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03157-3 · Cited by 568
Pregabalin Pharmacology and Its Relevance to Clinical Practice
Ben‐Menachem, E. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.455003.x · Cited by 542
Pharmacokinetic profile of levetiracetam
Patsalos, P. N. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00052-2 · Cited by 519
Self-citationProgress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
The importance of drug interactions in epilepsy therapy
Patsalos, P. N., Fröscher, W., Pisani, F., & Van Rijn, C. M. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.13001.x · Cited by 455
Self-citationPatsalos, P. N., & Perucca, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00409-5 · Cited by 423
Self-citationPatsalos, P. N., & Perucca, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00483-6 · Cited by 391
Self-citationLamotrigine substitution study: evidence for synergism with sodium valproate?
Brodie, M. J., & Yuen, A. W. C. (1997) · Epilepsy Research · doi:10.1016/s0920-1211(96)01007-8 · Cited by 379
Cited by
Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update
Patsalos, P. N., Spencer, E. P., & Berry, D. J. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000546 · Cited by 477
Self-citationAntiepileptic drug interactions—Principles and clinical implications
I. Johannessen, S., & Johannessen Landmark, C. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246254 · Cited by 343
Self-citationVeroniki, A. A., Cogo, E., Rios, P., Straus, S. E., Finkelstein, Y., Kealey, R., Reynen, E., Soobiah, C., Thavorn, K., Hutton, B., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0845-1 · Cited by 339
Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs
Zaccara, G., & Perucca, E. (2014) · Epileptic Disorders · doi:10.1684/epd.2014.0714 · Cited by 305
Metadata
- Authors
- Johannessen Landmark, C., & Patsalos, P. N.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2010-01
- Volume
- 10
- Issue
- 1
- Pages
- 119-140
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2132257746
- Cited by
- 321
- References
- 94
- FWCI
- 16.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug interactions involving the new second- and third-generation antiepileptic drugs. https://app.cochat.ai/papers/10.1586/ern.09.136
- The paper
- Johannessen Landmark, C., & Patsalos, P. N. (2010). Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Review of Neurotherapeutics. https://doi.org/10.1586/ern.09.136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.